| PACKAGING TYPE: | 15x10 (15 Strips In 1 Box) |
| COMPOSITION: | Clopidogrel Bisulphate Eq. To Clopidogrel 75 Mg & Aspirin 75 Mg |
| FORMULATION: | Tablet |
| Description: | CLOPINASE AP 75 Tablet is a combination antiplatelet medication containing Clopidogrel 75 mg (as Clopidogrel bisulphate) and Aspirin 75 mg. It is widely used for the prevention of blood clots in patients at high risk of cardiovascular events. Clopidogrel inhibits platelet aggregation by blocking ADP receptors, while Aspirin prevents platelet activation by inhibiting cyclooxygenase (COX). This dual antiplatelet therapy provides enhanced protection against heart attack, stroke, and complications after angioplasty or stent placement. |
| Side Effects: | Some individuals may experience: Increased risk of bleeding or bruising Gastric irritation or acidity Nausea Diarrhea Headache Serious side effects (rare) include severe bleeding, black stools, or allergic reactions—seek immediate medical attention if observed. |
| How to Use: | Take the tablet as prescribed by a healthcare professional. Swallow whole with water, preferably after meals. Take at the same time daily for consistent effect. Do not skip doses to ensure effective prevention. Follow the recommended duration strictly. |
| Precaution: | Use cautiously in patients with bleeding disorders or peptic ulcers. Inform your doctor before any surgery or dental procedures. Avoid use with other blood thinners unless prescribed. Monitor for signs of unusual bleeding or gastrointestinal issues. Pregnant or breastfeeding women should consult a healthcare professional before use. Avoid alcohol to reduce risk of gastric bleeding. |
| Product Benefits: | Provides dual antiplatelet action for superior clot prevention. Reduces risk of heart attack and stroke. Essential therapy after angioplasty and stent placement. Improves blood circulation in arteries. Supports long-term cardiovascular protection. |
Frequently Asked Questions
It is used to prevent blood clots, heart attacks, and strokes, especially in high-risk patients.
The combination provides enhanced antiplatelet effect compared to single-drug therapy.
Yes, it may increase the risk of bleeding due to dual antiplatelet action.




















